Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 22, 2018

Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006)

Laurence Mignon, Holly Kordasiewicz, Roger Lane, Anne Smith, Timothy Miller, Padma Narayanan, Eric Swayze, Daniel Norris, Bethany Fitzsimmons, Frank Bennett
First published April 9, 2018,
Laurence Mignon
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Kordasiewicz
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Lane
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Smith
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Miller
2Washington University Saint Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Padma Narayanan
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Swayze
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Norris
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethany Fitzsimmons
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bennett
1Ionis Pharmaceuticals, Inc Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006)
Laurence Mignon, Holly Kordasiewicz, Roger Lane, Anne Smith, Timothy Miller, Padma Narayanan, Eric Swayze, Daniel Norris, Bethany Fitzsimmons, Frank Bennett
Neurology Apr 2018, 90 (15 Supplement) S2.006;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To design a study to test IONIS-MAPTRx an antisense oligonucleotide (ASO) developed to specifically, potently and safely reduce MAPT mRNA in patients with tauopathies.

Background: Tau pathology is temporally and regionally related to neurodegeneration in Alzheimer disease (AD), emphasizing its role in transducing Aβ-linked neurotoxicity. Reducing Tau mRNA in all cell types will lead to reductions of any isoforms, post-translational modifications, and conformations of tau, thus potentially impacting all tauopathies. Homozygous and hemizygous knockout of endogenous tau in mice protects against Aβ insults. Treatment with ASO in a mouse model of human tauopathy leads to the reduction of the human MAPT pre-mRNA, blocking tau pathology, preventing seeding activity, reversing established tau pathology, extending survival and improving functional outcomes (DeVos et al. Science Translational Medicine, 2017).

Design/Methods: ASOs were designed and screened to identify the optimal drug candidate. Toxicology studies, performed in rodents and non-human primates, established the candidate’s safety, pharmacokinetic and pharmacodynamic profiles.

Results: IONIS-MAPTRx is a second generation 2′-O-methoxyethyl chimeric ASO designed to reduce tau expression. Intrathecal administrations of IONIS-MAPTRx in nonhuman primates showed a mean MAPT mRNA reduction of 77% in frontal cortex and 74% in hippocampus without dose-limiting side effects. These findings informed the design of the first clinical trial of this tau-lowering ASO. Ionis-MAPTRx CS1 (NCT03186989) is a multi-center, randomized, placebo-controlled multiple-ascending dose study assessing the safety, tolerability and pharmacokinetic parameters of repeated intrathecal injections in patients with mild AD. The study endpoints, including CSF biomarker, neuroimaging, and clinical outcomes, serve both as safety measures and as exploratory measures of pharmacodynamic effects.

Conclusions: IONIS-MAPTRx is the result of a comprehensive drug discovery effort to design a well-tolerated, potent ASO with high specificity to human MAPT mRNA. This promising therapeutic approach for primary and secondary tauopathies recently initiated dosing in patients with mild AD.

Disclosure: Dr. Mignon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Kordasiewcz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Lane has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Smith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics, Biogen, Ionis. Dr. Miller has received royalty, license fees, or contractual rights payments from C2N. Dr. Miller has received research support from Biogen. Dr. Narayanan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Swayze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Norris has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Fitzsimmons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals. Dr. Bennett has nothing to disclose.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (10)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise